| Autor: |
Gutch, Manish, Joshi, Abhay, Kumar, Sukriti, Agarwal, Avinash, Pahan, Rajendra Kumar, Razi, Syed Mohd |
| Předmět: |
|
| Zdroj: |
Indian Journal of Endocrinology & Metabolism; Nov/Dec2017, Vol. 21 Issue 6, p898-902, 5p |
| Abstrakt: |
The dipeptidyl peptidase-4 (DPP-4) inhibitors have facilitated the management of type 2 diabetes mellitus (T2DM) owing to their superior efficacy and safety with low incidence of adverse effects. Gemigliptin is a new member of this family of drugs, and studies have revealed certain advantages of gemigliptin use compared to its previous congeners. Besides, this drug has also been studied for the treatment of T2DM as monotherapy, in combination with metformin or other oral antidiabetic drugs and in T2DM with moderate-to-severe renal failure. In this review, we explore the published data highlighting the pharmacology, efficacy, and safety of gemigliptin along with its recommendations for use in patients with T2DM. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
